Glycostem Therapeutics' natural killer cell-based therapy oNKord was granted orphan drug designation by the FDA as a treatment for multiple myeloma. The treatment was also granted orphan drug status in 2016 to treat adults diagnosed with acute myeloid leukemia.
Glycostem's multiple myeloma therapy gains orphan tag
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.